Reinacher-Schick, AC, Lopez, MR, Alonso-Orduña, V, Lopez-Bravo, DP, Vergauwe, P, Tannapfel, A, Silveira, AB, Schlombs, K, Young, P, He, Y, Henn, H, Manning, L, Preussner, L, Mueller, F, Sahin, U, Türeci, O. Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Schreurs, MAC, Cajal, TRY, Adank, MA, Collée, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families (vol 73, 103611, 2024). BREAST. 2024; 75DOI:10.1016/j.breast.2024.103723. PMID:. IF:7.900(Q1/1D).

Aggarwal, C, Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny, E, Chu, QS, Monnet, I, Sanchez, A, Dakhil, SR, Camidge, DR, Pillet, M, Brown, M, Dowson, A, Cooper, ZA, Kumar, R, Herbst, RS. Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

Berciano-Guerrero, MA, Perez-Ruiz, E, Couselo, EM, Manzano, JL, Cerezuela-Fuentes, P, de Miguel, PA, Soria, A, Castaño, AG, Crespo, G, Puértolas, T, De La Rosa, CA, Sanz, LG, Castro, RL, Espinosa, E, Lecumberri, MJ, Majem, M, Martinez, JM, Bellido, L, Fernández-Morales, LA, Martin-Algarra, S. Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).